Unraveling Psychedelic Responses: Targeted Protein Degradation and Genetic Diversity.

This Viewpoint discusses the intersection of targeted protein degradation (TPD) technologies and psychedelic research. The resurgence in interest in psychedelics for treating mental disorders and the known genetic variability in responses require new strategies. TPD technologies might address this variability, modulating protein expressions based on genetic profiles. The discussion includes potential challenges in implementing TPD technologies in psychedelic research and potential strategies to address these issues. It considers lessons from COVID-19 research on genetic variability, proposing integration of TPD technologies into psychedelic research as a promising field despite these challenges, possibly leading to personalized treatments and improved patient outcomes. © 2023 American Chemical Society.

Citation

Robert B Kargbo. Unraveling Psychedelic Responses: Targeted Protein Degradation and Genetic Diversity. ACS medicinal chemistry letters. 2023 Aug 10;14(8):1017-1020

PMID: 37583820

search → result